Merck (MRK) PT Raised to $74 at JPMorgan

Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the companys Type II Variation, which seeks approval for KEYTRUDA, Mercks anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). The application was accepted for review based on overall survival (OS) and progression-free survival (PFS) data from the Phase 3 KEYNOTE-189 trial, which were recently... More

Goldman Sachs Double Upgrades Merck (MRK) to Conviction Buy

Goldman Sachs upgraded Merck (NYSE: MRK) from Neutral to Conviction Buy with a price target of $73.00 (from $63.00).

Analyst Jami Rubin raises his Keytruda estimates post AACR by $2 billion in 2021 and $4 billion in 2025 citing a significant rise in revenue and EPS estimates. He... More

UPDATE: Merck (MRK) PT Raised to $67 at Cowen

(Updated - April 20, 2018 8:07 AM EDT)

Cowen raised its price target on Merck (NYSE: MRK) to $67.00 (from $60.00) while maintaining a Market Perform rating. Post the standout KN-189 results presented at AACR, Cowen doubled forecasts for Keytruda share in metastatic 1L NSCLC, from 27% to 50%,... More

Merck (MRK) PT Lowered to $67 at Bernstein

Bernstein lowered its price target on Merck (NYSE: MRK) to $67.00 (from $69.00) while maintaining a Outperform rating.

Merck (MRK) PT Raised to $70 at BofA/Merrill Lynch, 'Merck emerging as clear IO winner in lung'

BofA/Merrill Lynch raised its price target on Merck (NYSE: MRK) to $70.00 (from $68.00) while maintaining a Buy rating.